Tissue Polypeptide Specific Antigen (TPS) a New Prognostic Tumor Marker for Patients with Prostate Cancer Metastases Underwent Androgen Deprivation

Abstract

rostate cancer is one of the most common types of cancer in men worldwide. However, the incidence rates varies and it is much more common in Europe and USA than in Asian countries. In the United States and Europe, prostate cancer is the most common type of cancer in men and the annual incidence rate is 110-120 per 100 000 men. The prognosis for prostate cancer is good. The 10-year survival rate is 93%, in case of early detection and accurate monitoring of the disease. PSA is an established marker for monitoring of prostate carcinoma after therapy. However, since production of PSA is androgen dependent, in patients on anti-androgen treatment, the PSA level does not always reflect the efficacy of the treatment. The cytokeratin marker TPS has in several studies shown to be a valuable complement to PSA, by enhancing early detection of recurrence, prognosis and Monitoring of Prostate Cancer. PSA and TPS express two different aspects of the